Pepsin A (Recombinant)

Recombinant Protein · expressed in HEK293
Citation tracking pending
Recombinant human Pepsin A (PGA5, EC 3.4.23.1; UniProt P00790) expressed in HEK293 cells. Used in gastric protease activity assays, inhibitor profiling, and as an antibody validation standard.
Expression system
HEK293
Cat. #
REC-PepsinA

In stock

SKU
REC-PepsinA
$498.00

Target Overview

Pepsin A (UniProt P00790; gene PGA5) is a gastric aspartic endoprotease and the predominant proteolytic enzyme secreted by the chief cells of the gastric mucosa. It is synthesised as an inactive zymogen, pepsinogen A, which undergoes autocatalytic cleavage of its N-terminal prosegment at acidic pH to yield the mature, active enzyme. Pepsin A cleaves peptide bonds preferentially at the N-terminal side of hydrophobic residues, enabling the initial digestion of dietary proteins in the stomach. This recombinant form is expressed in HEK293 mammalian cells, a system well suited to preserve the folding and glycosylation characteristics relevant to the human enzyme, and is supplied in a formulation compatible with standard biochemical assays. In the laboratory, this reagent is used primarily in three contexts. First, it serves as an active enzyme preparation for kinetic characterisation studies — researchers measure cleavage of fluorogenic or chromogenic peptide substrates (e.g., haemoglobin- or casein-based substrates) and determine apparent kcat/KM values. Second, it is employed in small-molecule inhibitor screens, where IC50 values can be determined against defined synthetic substrates under controlled pH conditions. Third, it functions as a well-characterised positive-control antigen for antibody validation experiments; researchers running Western blot or IHC panels with the Triple Point Biologics anti-Pepsin A antibody (SKU: RP-Pepsin A) can use this recombinant as a titrated loading standard to confirm band identity and assay sensitivity. The HEK293 expression system allows use of human-sequence protein in human-cell-line contexts, reducing species-mismatch concerns common with bacterially expressed material.

Background

Pepsin A (PGA5; EC 3.4.23.1) is the archetypal member of the aspartic protease family and has been a subject of biochemical investigation for over a century. Its two catalytic aspartate residues sit in a bilobed active-site cleft, and the enzyme operates optimally at pH 1.5–2.5, making it one of the few stable, active proteases under the extreme acidity of the gastric lumen. Beyond classical digestive physiology, pepsinogen and pepsin have attracted renewed research interest across several disease-relevant contexts. In gastroesophageal reflux disease (GERD) and Barrett's oesophagus, pepsin A is studied as a contributor to refluxate-mediated mucosal injury. Stabenau et al. (2023, Laryngoscope) demonstrated that co-expression of pepsinogen with proton pump components in Barrett's oesophageal cells induces cancer-associated molecular changes, illustrating how pepsinogen biology intersects with tumour-relevant cellular reprogramming and making this enzyme a studied target in oesophageal cancer research models. The broader pepsinogen gene family has also drawn attention in oncology. A pan-cancer transcriptomic analysis by Shen et al. (2020, Cancer Med) characterised differential expression patterns across the pepsinogen family — including PGA5 — in multiple tumour types, situating these genes as candidate research targets for tumour biology and biomarker studies. Recombinant Pepsin A is used in such studies as a biochemical reference to validate detection reagents and confirm assay specificity. In nutritional and digestive physiology research, pepsin activity is a standard readout for assessing gastrointestinal function. Studies examining dietary interventions — for example, Al-Khalaifah et al. (2020, BMC Vet Res), which evaluated effects of fermented feed ingredients on digestive gene expression and nutrient transporter activity in broiler models — use pepsin activity measurements as a functional endpoint, underscoring the enzyme's role as a benchmark in comparative digestive physiology. Researchers investigating gastric acid secretion, mucosa-protective mechanisms, or acid-peptic injury models rely on well-characterised enzyme preparations to produce reproducible data. This recombinant Pepsin A, produced in HEK293 cells, provides a defined, human-sequence reagent suited to those experimental designs. Researchers performing antibody-based detection of pepsin A in tissue or cell lysates can pair this recombinant with the matched Triple Point Biologics anti-Pepsin A antibody (SKU: RP-Pepsin A), which has been validated for Western blot applications over Triple Point Biologics' 32-year history of proteinase and inhibitor antibody development.

Applications

  • Fluorogenic peptide substrate cleavage assay (e.g., haemoglobin-FRET substrate) for kinetic characterisation (kcat, KM) under defined acidic pH conditions
  • Small-molecule inhibitor IC50 determination against synthetic chromogenic or fluorogenic pepsin substrates
  • Positive-control antigen for Western blot validation of anti-Pepsin A antibodies, including Triple Point Biologics SKU RP-Pepsin A
  • IHC antigen spike-in standard for confirming antibody specificity in gastric mucosal tissue sections
  • Substrate specificity profiling by mass spectrometry to map Pepsin A cleavage-site preferences across peptide libraries
  • Gastric refluxate model system — enzyme component for in vitro acid-peptic injury assays on oesophageal or airway epithelial cell lines
  • Comparative digestive physiology studies measuring pepsin activity as a functional endpoint alongside nutrient transporter gene expression data

References

  1. Stabenau KA et al. Pepsinogen/Proton Pump Co-Expression in Barrett's Esophageal Cells Induces Cancer-Associated Changes. Laryngoscope. 2023. doi:10.1002/lary.30109. PMID: 35315085.
  2. Shen S et al. The panoramic picture of pepsinogen gene family with pan-cancer. Cancer Med. 2020. doi:10.1002/cam4.3489. PMID: 33067881.
  3. Al-Khalaifah HS et al. Effects of graded levels of microbial fermented or enzymatically treated dried brewer's grains on growth, digestive and nutrient transporter genes expression and cost effectiveness in broiler chickens. BMC Vet Res. 2020. doi:10.1186/s12917-020-02603-0. PMID: 33153443.

Additional Specifications

Storage Buffer 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol
Endotoxin Level <0.1 EU/µg by LAL
Purity (%) >90% by SDS-PAGE
Expression System HEK293
Subcellular Localization Secreted; gastric chief cells

Frequently Asked Questions

What molecular weight band should I expect for recombinant Pepsin A on SDS-PAGE?

The mature, active form of Pepsin A (UniProt P00790; PGA5) runs at approximately 34–35 kDa under reducing SDS-PAGE conditions, consistent with the processed enzyme after autocatalytic removal of the N-terminal prosegment (~44 residues). The zymogen precursor, pepsinogen A, would run closer to 42 kDa, but this HEK293-expressed preparation is supplied as the active, prosegment-cleaved form. Because HEK293 cells support N-linked glycosylation, you may observe a slight upward shift or diffuse banding relative to the theoretical unglycosylated MW; a tight band at ~34–36 kDa is the expected result.

Is this recombinant Pepsin A supplied as the zymogen (pepsinogen) or mature active enzyme?

This preparation is the mature, active enzyme — not the zymogen. Pepsinogen A undergoes autocatalytic cleavage of its ~44-residue N-terminal prosegment below pH 5, and this recombinant is processed to that active state prior to formulation. It is supplied in 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol, where the enzyme is stable for storage but catalytically latent at neutral pH. Transfer to an acidic assay buffer (pH 2.0–4.0) is required to activate the enzyme for hydrolysis assays. Do not confuse the storage form with the inactive zymogen; no additional activation step is needed.

What substrates and assay buffer should I use to measure recombinant Pepsin A activity?

Pepsin A activity is most commonly measured at pH 2.0–3.5 in a citrate-phosphate or acetate assay buffer. The classic chromogenic substrate is acid-denatured hemoglobin (Anson assay), where released TCA-soluble peptides are quantified by Lowry or Folin reagent at ~660 nm. For fluorogenic kinetic assays, the internally quenched peptide substrate Lys-Pro-Ala-Glu-Phe-Nph-Ala-Leu (Mca/Dnp variants) is well characterized for aspartic proteases. Optimal pH is 2.0 for maximal velocity; activity drops sharply above pH 5 and is irreversibly denatured above pH 6. Use borosilicate or polypropylene vessels — Pepsin A adsorbs to certain plastics.

What starting concentration of recombinant Pepsin A should I use in a kinetic activity assay?

For initial rate kinetics with a fluorogenic peptide substrate, a working enzyme concentration of 1–5 nM in acidic assay buffer (pH 2.0–3.0) is a practical starting point, adjusting to keep reaction velocity in the linear range over 5–10 minutes. For the hemoglobin Anson assay, 0.01–0.1 µg/µL enzyme in 1 mL reaction volume at 37 °C for 10 minutes is a standard entry point. Titrate enzyme concentration to confirm linearity with respect to product formation before committing to inhibitor or mutant comparisons. This recombinant is supplied at ≥0.5 mg/mL; dilute immediately before use in pre-chilled acidic buffer.

How do I determine IC50 for a Pepsin A inhibitor using this recombinant?

Pre-incubate recombinant Pepsin A (1–2 nM final) with serial dilutions of your inhibitor at assay pH (2.0–3.5) for 15–30 minutes before initiating the reaction with substrate. For competitive inhibitors, ensure substrate concentration spans 0.3–3× Km to distinguish competitive from non-competitive mechanisms. Pepstatin A (Ki ~0.1 nM) is the standard positive-control inhibitor for aspartic proteases and should be included in every IC50 experiment as a benchmark. Avoid DMSO >1% v/v, which can artifactually reduce activity at acidic pH. Report IC50 values alongside substrate concentration used, as apparent IC50 shifts with [S] for competitive inhibitors.

Can I use recombinant Pepsin A as a positive control for Western blot with the TPB matched antibody?

Yes — this recombinant is the recommended positive control for the matched rabbit polyclonal antibody (SKU: RP-Pepsin A; /anti-pepsin-a-rabbit-polyclonal-antibody). Load 20–50 ng of recombinant Pepsin A per lane under reducing conditions; expect a clean band at ~34–36 kDa. The antibody and antigen are produced in the same laboratory and have been validated together for Western blot, so band identity is unambiguous. This pairing is particularly useful when setting up antibody dilutions against an unknown tissue lysate, giving you a defined-MW anchor band for normalization and ensuring you are detecting the mature enzyme form.

How much recombinant Pepsin A should I load for a Western blot positive control?

Load 20–50 ng per lane when using the matched antibody RP-Pepsin A under standard reducing SDS-PAGE conditions (4–12% or 10–15% Bis-Tris gels). At 20 ng, the band at ~34–36 kDa is readily detectable with an HRP-conjugated secondary at 1:5,000 and a standard ECL reagent with 1–3 minute exposure. If you are running gastric mucosal lysates alongside, load the recombinant control in a flanking lane rather than mixing, as the recombinant band may obscure closely migrating endogenous species. Do not boil the sample for more than 5 minutes — prolonged heating can cause aggregation artifacts above 100 kDa.

What are the storage and handling recommendations to preserve recombinant Pepsin A activity long-term?

Store at −20 °C in single-use aliquots immediately upon receipt. The formulation buffer — 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol — maintains enzyme stability at neutral pH and prevents aggregation during freeze-thaw. Repeated freeze-thaw cycles measurably reduce specific activity; prepare working aliquots at 10–50 µg to match your typical experiment scale. Once thawed, keep on ice and use within 8 hours; do not re-freeze a thawed aliquot. Activity benchmarking against a hemoglobin hydrolysis assay on receipt is advisable to establish a baseline before committing the material to screening campaigns. Endotoxin is <0.1 EU/µg by LAL.

Validation imagery coming soon

Western blot validation figures for REC-PepsinA will be published here as they are produced in-house.

If you would like to see existing validation data for this antibody before publication, request a sample copy.

  • Product Datasheet

    Full specifications, immunogen, validation, and recommended protocols.

    Request PDF →
  • Certificate of Analysis (COA)

    Lot-specific QC report. Available on request for any catalog lot.

    Request COA →
  • Safety Data Sheet (SDS)

    Handling, storage, and disposal guidance per regulatory standards.

    Request SDS →